Clinical Factors and the Outcome of Treatment with Methotrexate in Rheumatoid Arthritis: Role of Rheumatoid Factor, Erosive Disease and High Level of Erythrocyte Sedimentation Rate

• Published in: Journal of clinical medicine 2022-10, Vol.11 (20), p.6078
• Main Authors: Majorczyk, Edyta, Mazurek-Mochol, Małgorzata, Pawlik, Andrzej, Kuśnierczyk, Piotr
• Format: Article
• Language: English
• Subjects: Age; Amyloidosis; Antibodies; Biopsy; Dihydrofolate reductase; Disease; Drug dosages; Performance evaluation; Regression analysis; Remission (Medicine); Rheumatoid arthritis; Rheumatology
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm11206078

To identify the clinical factors predicting the outcome of treatment with methotrexate in rheumatoid arthritis, we examined 312 patients (253 females, 59 males) with rheumatoid arthritis diagnosed according to the criteria of the American College of Rheumatology. All patients included in this analysis began treatment with a regimen of oral MTX 7.5 mg weekly, with the dosage increasing to 15 mg weekly after 4 weeks, in combination with folic acid (1 mg daily). Good responders were defined as patients who had a DAS28 of ≤2.4 at 6 months (patients with remission of disease symptoms). Poor responders were defined as patients who had a DAS28 of >2.4. In this study, we analyzed the association between clinical parameters such as sex of patients, age of patients, age at disease onset, disease duration, rheumatoid factor, anti-CCP antibodies, ESR values, presence of joints erosions, presence of extra-articular manifestations and the response to MTX in RA patients. Multivariate logistic regression analysis showed four independent factors significantly associated with good response to MTX treatment: older age at disease onset, low ESR, no erosive disease and negative RF. The results of our study suggest that a younger age at disease onset, the presence of RF, erosive disease, as well as a high level of ESR are associated with worse response to MTX therapy.